Swedish Orphan Biovitrum AB (publ) (B6E.F)
| Previous Close | 23.74 |
| Open | 23.86 |
| Bid | 0.00 x 76000 |
| Ask | 24.18 x 74000 |
| Day's Range | 23.86 - 23.92 |
| 52 Week Range | 16.13 - 26.46 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | 8.192B |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 44.30 |
| EPS (TTM) | 0.54 |
| Earnings Date | Jul 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireSobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. Efanesoctocog alfa is a once-weekly and high-sustained factor VIII replacement therapy for patients of all ages and any disease severity.
PR NewswireSobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the first quarter 2024
PR NewswireNotice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Tuesday, 14 May 2024 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
